Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12701772 | 0.84 | ALDH1A1 (0.56) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL4659260 | 0.83 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2APIM1 | |
| SCHEMBL12701374 | 0.83 | HTR3A (0.55) | RAB9AKMT2AALDH1A1KDM4ECYP1A2 | |
| SCHEMBL12724325 | 0.80 | ALDH1A1 (0.52) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL28722024 | 0.79 | GAA (0.55) | KMT2APIM1GAASMN1; SMN2CNR2 | |
| SCHEMBL29496103 | 0.79 | GAA (0.55) | KMT2APIM1GAASMN1; SMN2CNR2 | |
| SCHEMBL4658361 | 0.77 | KDM4E (0.49) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL12701060 | 0.77 | KDM4E (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL12701400 | 0.76 | P2RX7 (0.45) | — | |
| SCHEMBL29495968 | 0.75 | GAA (0.50) | PIM1GAASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| US-8431704-B2 | Quinoline or isoquinoline substituted P2X7 antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-30 | — | — | US | disclosed |
| EP-2285800-B1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV | 2011-04-21 | — | — | US | disclosed |
| EP-2285800-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132000-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092481-A1 | QUINOLINE OR ISOQUINOLINE SUBSTITUTED P2X7 ANTAGONISTS | P2RX7, P2RX1, P2RX3 | NPC1 792/4885RAB9A 2577/4885MEN1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.